<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:54:04Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10765891" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10765891</identifier>
        <datestamp>2024-01-04</datestamp>
        <setSpec>bmccard</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMC Cardiovasc Disord</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMC Cardiovasc Disord</journal-id>
              <journal-title-group>
                <journal-title>BMC Cardiovascular Disorders</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1471-2261</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10765891</article-id>
              <article-id pub-id-type="pmcid">PMC10765891</article-id>
              <article-id pub-id-type="pmc-uid">10765891</article-id>
              <article-id pub-id-type="pmid">38172712</article-id>
              <article-id pub-id-type="pmid">38172712</article-id>
              <article-id pub-id-type="publisher-id">3623</article-id>
              <article-id pub-id-type="doi">10.1186/s12872-023-03623-y</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Circulating sphingolipids and relationship to cardiac remodelling before and following a low-energy diet in asymptomatic Type 2 Diabetes</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brady</surname>
                    <given-names>Emer M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cao</surname>
                    <given-names>Thong H.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moss</surname>
                    <given-names>Alastair J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Athithan</surname>
                    <given-names>Lavanya</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ayton</surname>
                    <given-names>Sarah L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Redman</surname>
                    <given-names>Emma</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Argyridou</surname>
                    <given-names>Stavroula</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Graham-Brown</surname>
                    <given-names>Matthew P. M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Maxwell</surname>
                    <given-names>Colleen B.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jones</surname>
                    <given-names>Donald J. L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ng</surname>
                    <given-names>Leong</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yates</surname>
                    <given-names>Thomas</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Davies</surname>
                    <given-names>Melanie J</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McCann</surname>
                    <given-names>Gerry P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Gulsin</surname>
                    <given-names>Gaurav S.</given-names>
                  </name>
                  <address>
                    <email>gg149@leicester.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.412925.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0400 6581</institution-id><institution>Department of Cardiovascular Sciences, </institution><institution>University of Leicester, NIHR Leicester Biomedical Research Centre, Glenfield Hospital, </institution></institution-wrap>Leicester, LE3 9QP UK </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04h699437</institution-id><institution-id institution-id-type="GRID">grid.9918.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8411</institution-id><institution>Leicester Van Geest Multi-Omics Facility, </institution><institution>University of Leicester, </institution></institution-wrap>Leicester, UK </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412934.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0400 6629</institution-id><institution>Diabetes Research Centre, </institution><institution>NIHR Leicester Biomedical Research Centre, Leicester General Hospital, </institution></institution-wrap>Leicester, UK </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>3</day>
                <month>1</month>
                <year>2024</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>3</day>
                <month>1</month>
                <year>2024</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2024</year>
              </pub-date>
              <volume>24</volume>
              <elocation-id>25</elocation-id>
              <history>
                <date date-type="received">
                  <day>18</day>
                  <month>8</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>19</day>
                  <month>11</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2023</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">Heart failure with preserved ejection fraction (HFpEF) is a heterogenous multi-system syndrome with limited efficacious treatment options. The prevalence of Type 2 diabetes (T2D) continues to rise and predisposes patients to HFpEF, and HFpEF remains one of the biggest challenges in cardiovascular medicine today. Novel therapeutic targets are required to meet this important clinical need. Deep phenotyping studies including -OMIC analyses can provide important pathogenic information to aid the identification of such targets. The aims of this study were to determine; 1) the impact of a low-energy diet on plasma sphingolipid/ceramide profiles in people with T2D compared to healthy controls and, 2) if the change in sphingolipid/ceramide profile is associated with reverse cardiovascular remodelling.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">Post-hoc analysis of a randomised controlled trial (NCT02590822) including adults with T2D with no cardiovascular disease who completed a 12-week low-energy (∼810 kcal/day) meal-replacement plan (MRP) and matched healthy controls (HC). Echocardiography, cardiac MRI and a fasting blood for lipidomics were undertaken <italic>pre</italic>/<italic>post</italic>-intervention. Candidate biomarkers were identified from case–control comparison (fold change &gt; 1.5 and statistical significance <italic>p</italic> &lt; 0.05) and their response to the MRP reported. Association between change in biomarkers and change indices of cardiac remodelling were explored.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">Twenty-four people with T2D (15 males, age 51.1 ± 5.7 years), and 25 HC (15 male, 48.3 ± 6.6 years) were included. Subjects with T2D had increased left ventricular (LV) mass:volume ratio (0.84 ± 0.13 vs. 0.70 ± 0.08, <italic>p</italic> &lt; 0.001), increased systolic function but impaired diastolic function compared to HC. Twelve long-chain polyunsaturated sphingolipids, including four ceramides, were downregulated in subjects with T2D at baseline. Three sphingomyelin species and all ceramides were inversely associated with LV mass:volume. There was a significant increase in all species and shift towards HC following the MRP, however, none of these changes were associated with reverse cardiac remodelling.</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p id="Par4">The lack of association between change in sphingolipids/ceramides and reverse cardiac remodelling following the MRP casts doubt on a causative role of sphingolipids/ceramides in the progression of heart failure in T2D.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p id="Par5">NCT02590822.</p>
                </sec>
                <sec>
                  <title>Supplementary Information</title>
                  <p>The online version contains supplementary material available at 10.1186/s12872-023-03623-y.</p>
                </sec>
              </abstract>
              <abstract id="Abs2" abstract-type="highlights">
                <title>Highlights</title>
                <p id="Par6">• This study sheds light on the emerging link between dysregulated sphingolipid/ceramide metabolism and the development of heart failure (HF) in individuals with type 2 diabetes (T2D).</p>
                <p id="Par7">• Leveraging the gold standard assessment tool, cardiac MRI, this study is one of the first to explore plasma sphingolipid/ceramide in relation to measures of cardiovascular structure and function.</p>
                <p id="Par8">• The findings reveal that working-aged adults with T2D and Stage A/B HF exhibit disrupted fatty acid metabolism, characterized by reduced levels of long-chain polyunsaturated sphingomyelin/ceramide species.</p>
                <p id="Par9">• Importantly, this study challenges the notion of a causative role of sphingolipids/ceramides in the progression of heart failure in T2D.</p>
                <sec>
                  <title>Supplementary Information</title>
                  <p>The online version contains supplementary material available at 10.1186/s12872-023-03623-y.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Diabetic cardiomyopathy</kwd>
                <kwd>Stage B heart failure</kwd>
                <kwd>Sphingolipids</kwd>
                <kwd>Ceramide</kwd>
                <kwd>Cardiac MRI</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000272</institution-id>
                      <institution>National Institute for Health and Care Research</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>CDF 2014-07-045</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Davies</surname>
                      <given-names>Melanie J</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id>
                      <institution>British Heart Foundation</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>FS/16/47/32190</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>McCann</surname>
                      <given-names>Gerry P.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© BioMed Central Ltd., part of Springer Nature 2024</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Background</title>
              <p id="Par10">Type 2 diabetes (T2D) is recognised as one of the most important risk factors for heart failure (HF) [<xref ref-type="bibr" rid="CR1">1</xref>]. Indeed, the recent universal guidelines for definition of HF has classified all people with T2D as Stage A “at risk” of HF and those with asymptomatic cardiac structural and/or functional alterations as Stage B HF [<xref ref-type="bibr" rid="CR2">2</xref>]. People with T2D have a propensity for HF with preserved ejection fraction (HFpEF) [<xref ref-type="bibr" rid="CR3">3</xref>], a heterogeneous clinical syndrome [<xref ref-type="bibr" rid="CR4">4</xref>], which remains one of the biggest challenges in cardiovascular medicine, given the limited efficacious treatment options. Novel therapeutic targets are required to meet this important clinical need. Deep phenotyping studies including -OMIC analyses can provide information on the underpinning pathogenic mechanisms early in a disease course, track response to intervention and thus aid the identification of such targets [<xref ref-type="bibr" rid="CR5">5</xref>] .</p>
              <p id="Par11">Dysregulated lipid pathways within cardiomyocytes are considered a potential pathogenic process in the development of HFpEF in the context of T2D [<xref ref-type="bibr" rid="CR6">6</xref>]. Moreover, complex sphingolipids, and more specifically, dysregulation of ceramide and sphingolipid metabolism are thought to have a cardiotoxic role in the pathogenesis of HF [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR10">10</xref>]. In a small subset of the Alberta Heart study, circulating levels of 14 species of sphingomyelins in people with symptomatic HFpEF (10/24 with T2D) were lower than controls without HF. Further, logistic regression analysis showed that sphingomyelin (C20:2) could discriminate between those with HFpEF and the non-HF controls [<xref ref-type="bibr" rid="CR11">11</xref>]. Whether or not such signals can be identified in earlier stages of HF and the response to lifestyle intervention are unknown.</p>
              <p id="Par12">We have recently demonstrated, in participants randomised to a 12-week nutritionally complete low-energy (810kCal/day) meal replacement plan (MRP), not only did 80% acheive a normoglycaemic range but there was evidence of beneficial cardiovascular reverse remodelling [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. This cohort of participants with T2D, and Stage A/B HF, provides an opportunity to explore lipidomic signals and potential underlying pathogenic mechanisms in early HF.</p>
              <p id="Par13">The aims of this <italic>post-hoc</italic> discovery study were to determine if; 1) following an MRP the ceramide/sphingolipid profile harmonises with a healthy profile, and if 2) the change in ceramide/sphingolipid profile is associated with reverse cardiovascular remodelling.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <p id="Par14">This is a discovery metabolomics pilot study of the Diabetes Interventional Assessment of Slimming or Training tO Lessen Inconspicuous Cardiovascular Dysfunction (DIASTOLIC) trial. [<xref ref-type="bibr" rid="CR12">12</xref>] DIASTOLIC was a prospective, randomised, open-label, blinded end-point trial with published protocol and main outcomes paper [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. For this <italic>post-hoc</italic> analysis, only those randomised to and completing the MRP were included, in addition to age-, sex- and ethnicity-matched healthy controls for baseline comparison. Participants receiving the MRP were adults (18–65yrs) with established T2D (≥ 3 months) and obesity without prevalent cardiovascular disease (CVD). The study received ethical approval by the United Kingdom National Research Ethics Service (15/WM/0222) and is registered with <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> (NCT02590822). Consort diagram for the trial for this analysis is shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Study CONSORT diagram</p></caption><graphic xlink:href="12872_2023_3623_Fig1_HTML" id="MO1"/></fig></p>
              <sec id="Sec3">
                <title>Demographics, anthropometrics and biochemistry</title>
                <p id="Par15">Demographics, medical history, and anthropometric measures were collected as described previously [<xref ref-type="bibr" rid="CR14">14</xref>]. Fasting blood samples were obtained and the residual supernatant plasma stored at -80˚C prior to batch analysis. HbA1c, glucose, liver, kidney function and lipid profile were analysed according to standard operating procedures in the accredited pathology laboratory at University Hospitals Leicester NHS Trust. Insulin was quantified by multiplex assay on a Luminex platform, as previously described [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
              </sec>
              <sec id="Sec4">
                <title>Cardiovascular MRI</title>
                <p id="Par16">MRI scans were conducted on a 1.5T platform (MAGNETOM Aera; Siemens, Erlangen, Germany) as previously described [<xref ref-type="bibr" rid="CR14">14</xref>]. Images were analysed offline blinded to treatment group. The MRI outcomes of interest (<xref rid="MOESM1" ref-type="media">supplementary material</xref>: Cardiac MRI outcome measures) were selected to permit investigation of cardiovascular structure and function.</p>
              </sec>
              <sec id="Sec5">
                <title>Transthoracic echocardiography</title>
                <p id="Par17">Echocardiography was performed and interpreted by one of two accredited operators using an iE33 system with S5-1 transducer (Philips Medical Systems, Best, the Netherlands) to estimate Left Ventricular (LV) filling pressures (E/e').</p>
              </sec>
              <sec id="Sec6">
                <title>Metabolomics platform</title>
                <p id="Par18">Metabolon (North Carolina, USA) performed the metabolomic profiling. Samples were prepared using the automated MicroLab STAR® system from Hamilton Company. Sample analysis utilized a Waters ACQUITY ultra-performance liquid chromatography (UPLC), and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer, interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution.</p>
              </sec>
              <sec id="Sec7">
                <title>Statistics</title>
                <p id="Par19">The distribution of the data were assessed for normality using histograms and Q-Q plots. Continuous data are reported as mean (± standard deviation (SD)) if normally distributed or median (interquartile range (IQR)) where not, categorical data reported as count (percentage). Demographic and standard clinical characteristics between the cases (T2D) and controls are described without testing for statistical significance given these were not specific aims being assessed. For measures of cardiovascular structure and function, between groups were tested using independent t-test and Mann–Whitney U as appropriate. The metabolomic data were restricted to lipid species to answer the specified a priori research questions. Principal component analyses (PCA) were conducted to determine if there were separation between the cases (T2D) and healthy controls (controls) at baseline, and between pre-, post-MRP in those with T2D based on the lipid profiles. The fold-change between cases and controls and between pre-, and post-MRP were calculated with adjustment for false discovery rate (FDR) of 0.05 and volcano plots generated. Candidate biomarkers were classified as lipids with FDR adjusted fold change &gt; 1.5 (between case–control) with statistical significance <italic>p</italic> &lt; 0.05. Any biomarkers with a conflict in fold-change between the two comparisons were removed. The lipids were then further restricted to sphingolipid/ceramide species because these were the lipids of interest for this pilot study. The circulating plasma levels of the candidate biomarkers post-intervention were then investigated to determine their response to the MRP. Box plots were produced to visualise the concentration (signal intensity) of candidate biomarkers pre-, post-MRP and for healthy controls. Pearson’s or Spearman’s rank correlations were used (as appropriate) to examine relationships between plasma levels of candidate biomarkers and Left Ventricular mass:volume ratio, global longitudinal strain, global circumferential strain, longitudinal peak early diastolic strain rate, circumferential peak early diastolic strain rate, myocardial perfusion reserve and diastolic function (average E/e’). Univariate linear regression was employed to explore if the change in candidate sphingolipid/ceramide species were associated with change in the same measures of cardiovascular structure and function and significant univariate associations were then adjusted for baseline value.</p>
                <p id="Par20">Data were analysed using IBM SPSS Statistics for Windows, Version 26.0 and RStudio version 1.4. SIMCA version 14 (MSK Umetrics, Sweden) was used to perform PCA plots.</p>
              </sec>
            </sec>
            <sec id="Sec8">
              <title>Results</title>
              <sec id="Sec9">
                <title>Case–control analysis</title>
                <p id="Par21">Twenty-nine asymptomatic T2D participants (cases) were randomised to the MRP group with 24 completing the study with metabolomics data. Twenty-five matched controls (age, sex and ethnicity) were selected for metabolomics analysis (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The baseline characteristics by group are provided in Table <xref rid="Tab1" ref-type="table">1</xref>. At baseline, as expected, cases had higher body weight, blood pressure, HbA1c and insulin resistance with over half having hypertension and high cholesterol compared to none in the healthy group. Diabetes medication included one person with diet and lifestyle only (4%), 18 (75%) on monotherapy, three (13%) on dual therapy and two (8%) on triple therapy. No patients were taking insulin and only one and two were on Glucagon Like Peptide-1-Receptor agonists or Sodium-Glucose co-transporter 2 inhibitors, respectively. None of the healthy controls were taking any medications.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics table (cases and control)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><bold>Variable</bold></th><th align="left"><bold>Cases (T2D) </bold><bold><italic>N</italic></bold><bold> = 24</bold></th><th align="left"><bold>Controls (healthy) </bold><bold><italic>N</italic></bold><bold> = 25</bold></th><th align="left"/></tr></thead><tbody><tr><td align="left" colspan="4">Clinical characteristics</td></tr><tr><td align="left"> Age (years)</td><td align="left">51.1 ± 5.7</td><td align="left">48.3 ± 6.6</td><td align="left" rowspan="11"/></tr><tr><td align="left"> Sex (M (%))</td><td align="left">15 (63)</td><td align="left">15 (60)</td></tr><tr><td align="left"> Ethnicity (WE (%))</td><td align="left">15 (63)</td><td align="left">17 (68)</td></tr><tr><td align="left"> Weight (kg)</td><td align="left">106.7 ± 16.2</td><td align="left">69.9 ± 11.4</td></tr><tr><td align="left"> BMI (kg/m2)</td><td align="left">37.4 ± 5.9</td><td align="left">24.3 ± 2.5</td></tr><tr><td align="left"> Systolic BP (mmHg)</td><td align="left">145.9 ± 15.9</td><td align="left">118.4 ± 10.7</td></tr><tr><td align="left"> Diastolic BP (mmHg)</td><td align="left">91.1 ± 7.4</td><td align="left">76.2 ± 6.0</td></tr><tr><td align="left"> Heart rate (bpm)</td><td align="left">73.1 ± 8.6</td><td align="left">61.8 ± 9.3</td></tr><tr><td align="left"> HbA1c (%)</td><td align="left">7.2 ± 1.1</td><td align="left">5.4 ± 0.2</td></tr><tr><td align="left"> HbA1c (mmol/mol)</td><td align="left">54.8 ± 11.9</td><td align="left">35.6 ± 2.6</td></tr><tr><td align="left"> HOMAR-IR</td><td align="left">12.2 ± 8.2</td><td align="left">2.0 ± 1.9</td></tr><tr><td align="left" colspan="4">Medical history</td></tr><tr><td align="left"> Duration diabetes (m)</td><td align="left">58.3 ± 39.8</td><td align="left">-</td><td align="left" rowspan="4"/></tr><tr><td align="left"> Smoking history (yes)</td><td align="left">10 (41)</td><td align="left">7 (28)</td></tr><tr><td align="left"> Hypertension (n (%))</td><td align="left">15 (63)</td><td align="left">0 (0)</td></tr><tr><td align="left"> Hypercholesterolemia (n (%))</td><td align="left">16 (67)</td><td align="left">0 (0)</td></tr><tr><td align="left">Cardiovascular Imaging</td><td align="left"/><td align="left"/><td align="left"><italic>P</italic> value</td></tr><tr><td align="left"> LV Massi (g/m<sup>2</sup>)</td><td align="left">58.2 ± 9.8</td><td align="left">57.8 ± 13.1</td><td char="." align="char">0.902</td></tr><tr><td align="left"> LV EDVi (mL/m<sup>2</sup>)</td><td align="left">69.9 ± 11.3</td><td align="left">82.9 ± 18.0</td><td char="." align="char"><bold>0.004</bold></td></tr><tr><td align="left"> LV mass:volume (g/mL)</td><td align="left">0.84 ± 0.13</td><td align="left">0.70 ± 0.08</td><td char="." align="char"><bold>&lt; 0.001</bold></td></tr><tr><td align="left"> LV EF (%)</td><td align="left">70.0 ± 7.4</td><td align="left">64.7 ± 4.9</td><td char="." align="char">0.005</td></tr><tr><td align="left"> LV GLS (%)</td><td align="left">16.6 ± 2.8</td><td align="left">17.6 ± 1.5</td><td char="." align="char">0.108</td></tr><tr><td align="left"> LV GCS (%)</td><td align="left">21.0 ± 2.3</td><td align="left">19.6 ± 2.0</td><td char="." align="char"><bold>0.029</bold></td></tr><tr><td align="left"> LV LongPEDSR (s-1)</td><td align="left">0.79 ± 0.15</td><td align="left">0.89 ± 0.16</td><td char="." align="char"><bold>0.021</bold></td></tr><tr><td align="left"> LV CircPEDSR (s-1)</td><td align="left">1.00 ± 0.20</td><td align="left">1.10 ± 0.16</td><td char="." align="char">0.060</td></tr><tr><td align="left"> LAVImax (mL/ m2)*</td><td align="left">30.4 (10.4)</td><td align="left">50.6 (16.8)</td><td char="." align="char"><bold>&lt; 0.001</bold></td></tr><tr><td align="left"> LA EF (%)</td><td align="left">55.0 ± 7.7</td><td align="left">59.1 ± 7.8</td><td char="." align="char">0.075</td></tr><tr><td align="left"> Mean Ao Distens (mmHg<sup>−1</sup> × 10<sup>–3</sup>)</td><td align="left">3.7 ± 1.9</td><td align="left">6.9 ± 2.0</td><td char="." align="char"><bold>&lt; 0.001</bold></td></tr><tr><td align="left"> MPR</td><td align="left">3.0 ± 1.0</td><td align="left">4.2 ± 1.0</td><td char="." align="char"><bold>&lt; 0.001</bold></td></tr><tr><td align="left"> Average E/e'*</td><td align="left">9.4 (4.5)</td><td align="left">5.9 (2.6)</td><td char="." align="char"><bold>&lt; 0.001</bold></td></tr></tbody></table><table-wrap-foot><p>Data are reported as mean ± standard deviation, count (percent) or median (interquartile range). Bold font highlights statistically significant difference with significance level of 95%</p><p><italic>Abbreviations</italic>: <italic>BMI</italic> body mass index, <italic>LV EF</italic> Left ventricular ejection fraction, <italic>LV Massi</italic> Left Ventricular Mass Indexed for body surface area, <italic>mass:volume </italic>mass to volume ratio, <italic>LV EDVi</italic> Left Ventricular End Diastolic Volume indexed for height, <italic>GLS</italic> global longitudinal strain, <italic>LongPEDSR</italic> Longitudinal Peak Early Diastolic Strain Rate, <italic>CircPEDSR</italic> Circumferential Peak Early Diastolic Strain Rate, <italic>GCS</italic> global circumferential strain, <italic>LAVImax</italic> Left atrial maximum volume indexed for body surface area, <italic>Mean Ao Distens</italic> Mean aortic distensibility, <italic>MPR</italic> Myocardial perfusion reserve</p></table-wrap-foot></table-wrap></p>
                <p id="Par22">There was evidence of cardiovascular remodelling in those with T2D who had significantly lower left ventricular volume, higher mass:volume ratio with higher ejection fraction and global strain but worse diastolic function (LV filling pressures (E/é) and peak early diastolic strain rate). In addition, there was decreased aortic distensibility and lower myocardial perfusion reserve in T2D compared to the controls.</p>
              </sec>
              <sec id="Sec10">
                <title>Lipids</title>
                <p id="Par23">The metabolon platform returned 339 lipids species, of which 110 were significantly different between cases and controls (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a); 78 were significantly downregulated and 32 significantly upregulated in cases versus controls. There was good separation in discriminating between the groups based on these lipid species (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b) of which a total of forty-four had a fold-changes &gt; 1.5 meeting statistical significance adjusted for FDR of 0.05 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a: red-points only).<fig id="Fig2"><label>Fig. 2</label><caption><p>Volcano plot for all 339 identified lipids at baseline. Principal component plot for the 110 lipids differentially expressed between cases-controls</p></caption><graphic xlink:href="12872_2023_3623_Fig2_HTML" id="MO2"/></fig></p>
              </sec>
              <sec id="Sec11">
                <title>Pre-post MRP</title>
                <p id="Par24">Twenty-four cases completed the MRP intervention and had plasma for metabolomic analysis. There were significant cardio-metabolic improvements including weight loss (13.6kg), reduced blood pressure (13mmHg systolic), reduced arterial stiffness, reduced concentric remodelling, decreased insulin resistance and fasting glucose (-1.9mmol), with 20 (83%) participants in this group achieving normoglycaemia by 12 weeks (Supplemental material Table S<xref rid="MOESM1" ref-type="media">1</xref>), as previously reported [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
                <p id="Par25">Of the 110 candidate biomarkers identified in the case–control comparison, 25 were significantly different following the 12-week MRP. Following removal of conflicts in fold-change between the comparisons a final 23 candidate biomarkers were identified (Table <xref rid="Tab2" ref-type="table">2</xref>). Restricting analyses to these 23 candidate biomarkers there is a good separation between pre-, post-MRP (Fig. <xref rid="Fig3" ref-type="fig">3</xref>; Green and blue dots only) and evidence of a shift towards the healthy volunteers following the MRP (Fig. <xref rid="Fig3" ref-type="fig">3</xref>; Green, blue and red dots). We then further restricted the analysis to the sphingolipids and ceramides species (Table <xref rid="Tab2" ref-type="table">2</xref>), given the focus of these analysis. All 12 species contain one long chain (&gt; 16 Carbon atoms) unsaturated (≥ 1 double bond) fatty acid. The aforementioned shift towards healthy levels is observed in all the 12 species as demonstrated in box-plots in Fig. <xref rid="Fig4" ref-type="fig">4</xref>a and b. All 12 of these candidate biomarkers were significantly lower at baseline and increased to near ‘normal’ levels following the 12-week MRP.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>List of 23 lipid candidate biomarkers with significant fold-change &gt; 1.5 following the 12-week MRP</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>No</italic></th><th align="left"><italic>BIOCHEMICAL</italic></th><th align="left"><italic>COMP ID</italic></th><th align="left"><italic>Sub-family</italic></th><th align="left"><italic>Fold Change</italic></th><th align="left"><italic>Direction Δ from BL</italic></th><th align="left"><italic>Adjusted P value (FDR</italic> = <italic>0.05)</italic></th></tr></thead><tbody><tr><td align="left"><italic>1</italic></td><td align="left">nisinate (24:6n3)</td><td align="left">57810</td><td align="left">Long Chain Polyunsaturated Fatty Acid (n3 and n6)</td><td align="left">-2.08</td><td align="left">↓</td><td char="." align="char">0.005</td></tr><tr><td align="left"><italic>2</italic></td><td align="left">1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)</td><td align="left">52682</td><td align="left">Plasmalogen</td><td align="left">0.81</td><td align="left">↑</td><td char="." align="char">0.002</td></tr><tr><td align="left"><italic>3</italic></td><td align="left">1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1)</td><td align="left">52478</td><td align="left">Plasmalogen</td><td align="left">0.71</td><td align="left">↑</td><td char="." align="char">&lt; 0.001</td></tr><tr><td align="left"><italic>4</italic></td><td align="left">1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)</td><td align="left">52713</td><td align="left">Plasmalogen</td><td align="left">0.77</td><td align="left">↑</td><td char="." align="char">&lt; 0.001</td></tr><tr><td align="left"><italic>5</italic></td><td align="left">1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)</td><td align="left">52716</td><td align="left">Plasmalogen</td><td align="left">0.80</td><td align="left">↑</td><td char="." align="char">0.003</td></tr><tr><td align="left"><italic>6</italic></td><td align="left">1-(1-enyl-palmitoyl)-GPC (P-16:0)</td><td align="left">52474</td><td align="left">Lysoplasmalogen</td><td align="left">0.64</td><td align="left">↑</td><td char="." align="char">0.004</td></tr><tr><td align="left"><italic>7</italic></td><td align="left">1-palmitoyl-2-oleoyl-GPE (16:0/18:1)</td><td align="left">19263</td><td align="left">Phosphatidylethanolamine (PE)</td><td align="left">-1.55</td><td align="left">↓</td><td char="." align="char">0.003</td></tr><tr><td align="left"><italic>8</italic></td><td align="left">1-stearoyl-2-oleoyl-GPE (18:0/18:1)</td><td align="left">42448</td><td align="left">Phosphatidylethanolamine (PE)</td><td align="left">-1.88</td><td align="left">↓</td><td char="." align="char">0.001</td></tr><tr><td align="left"><italic>9</italic></td><td align="left">butyrylcarnitine (C4)</td><td align="left">32412</td><td align="left">Fatty Acid Metabolism</td><td align="left">-1.39</td><td align="left">↓</td><td char="." align="char">0.005</td></tr><tr><td align="left"><italic>10</italic></td><td align="left">dihomo-linoleoylcarnitine (C20:2)</td><td align="left">57520</td><td align="left">Fatty Acid Metabolism (Acyl Carnitine, Polyunsaturated)</td><td align="left">0.72</td><td align="left">↑</td><td char="." align="char">0.003</td></tr><tr><td align="left"><italic>11</italic></td><td align="left">eicosenoylcarnitine (C20:1)</td><td align="left">57519</td><td align="left">Fatty Acid Metabolism (Acyl Carnitine, Monounsaturated)</td><td align="left">0.69</td><td align="left">↑</td><td char="." align="char">0.002</td></tr><tr><td align="left"><italic>12</italic></td><td align="left">hydroxypalmitoyl sphingomyelin (d18:1/16:0(OH))</td><td align="left">62851</td><td align="left">Sphingomyelins</td><td align="left">0.85</td><td align="left">↑</td><td char="." align="char">0.004</td></tr><tr><td align="left"><italic>13</italic></td><td align="left">sphingomyelin (d18:1/20:2, d18:2/20:1, d16:1/22:2)</td><td align="left">57481</td><td align="left">Sphingomyelins</td><td align="left">0.70</td><td align="left">↑</td><td char="." align="char">0.001</td></tr><tr><td align="left"><italic>14</italic></td><td align="left">sphingomyelin (d18:1/22:2, d18:2/22:1, d16:1/24:2)</td><td align="left">57477</td><td align="left">Sphingomyelins</td><td align="left">0.80</td><td align="left">↑</td><td char="." align="char">0.002</td></tr><tr><td align="left"><italic>15</italic></td><td align="left">sphingomyelin (d18:2/16:0, d18:1/16:1)</td><td align="left">42459</td><td align="left">Sphingomyelins</td><td align="left">0.89</td><td align="left">↑</td><td char="." align="char">0.004</td></tr><tr><td align="left"><italic>16</italic></td><td align="left">sphingomyelin (d18:2/18:1)</td><td align="left">57474</td><td align="left">Sphingomyelins</td><td align="left">0.83</td><td align="left">↑</td><td char="." align="char">0.004</td></tr><tr><td align="left"><italic>17</italic></td><td align="left">sphingomyelin (d18:2/23:1)</td><td align="left">57482</td><td align="left">Sphingomyelins</td><td align="left">0.85</td><td align="left">↑</td><td char="." align="char">0.007</td></tr><tr><td align="left"><italic>18</italic></td><td align="left">sphingomyelin (d18:2/24:1, d18:1/24:2)</td><td align="left">52437</td><td align="left">Sphingomyelins</td><td align="left">0.80</td><td align="left">↑</td><td char="." align="char">&lt; 0.001</td></tr><tr><td align="left"><italic>19</italic></td><td align="left">sphingomyelin (d18:2/24:2)</td><td align="left">57479</td><td align="left">Sphingomyelins</td><td align="left">0.73</td><td align="left">↑</td><td char="." align="char">&lt; 0.001</td></tr><tr><td align="left"><italic>20</italic></td><td align="left">glycosyl ceramide (d18:2/24:1, d18:1/24:2)</td><td align="left">57453</td><td align="left">Hexosylceramides (HCER)</td><td align="left">0.71</td><td align="left">↑</td><td char="." align="char">0.001</td></tr><tr><td align="left"><italic>21</italic></td><td align="left">glycosyl-N-nervonoyl-sphingosine (d18:1/24:1)</td><td align="left">57369</td><td align="left">Hexosylceramides (HCER)</td><td align="left">0.72</td><td align="left">↑</td><td char="." align="char">&lt; 0.001</td></tr><tr><td align="left"><italic>22</italic></td><td align="left">lactosyl-N-nervonoyl-sphingosine (d18:1/24:1)</td><td align="left">57370</td><td align="left">Lactosylceramides (LCER)</td><td align="left">0.76</td><td align="left">↑</td><td char="." align="char">0.001</td></tr><tr><td align="left"><italic>23</italic></td><td align="left">lactosyl-N-palmitoyl-sphingosine (d18:1/16:0)</td><td align="left">53010</td><td align="left">Lactosylceramides (LCER)</td><td align="left">0.76</td><td align="left">↑</td><td char="." align="char">&lt; 0.001</td></tr></tbody></table><table-wrap-foot><p>Lipids with statistically significant fold-change pre- to post-MRP (calculated as baseline/week 12)</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig. 3</label><caption><p>Principal component plot for all 23 identified lipids for case (pre-MRP and post-MRP) and healthy controls</p></caption><graphic xlink:href="12872_2023_3623_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Box plots for plasma levels of candidate sphingolipids and ceramides for Type 2 Diabetes (pre-, post-MRP) and healthy controls</p></caption><graphic xlink:href="12872_2023_3623_Fig4_HTML" id="MO4"/></fig></p>
              </sec>
              <sec id="Sec12">
                <title>Cardiac remodelling and candidate biomarkers</title>
                <p id="Par26">In the baseline correlation analysis, for the pooled subjects (n = 49), three candidate sphingolipids and the four ceramide species were inversely correlated with LV mass: volume ratio (Table <xref rid="Tab3" ref-type="table">3</xref>). Four sphingolipids and one ceramide were positively correlated to longitudinal PEDSR. In addition to these species a further three sphingolipids (total of seven) and the same ceramide species were also positively correlated to circumferential PEDSR. Finally, the ceramide, lactosyl-N-palmitoyl-sphingosine, was positively correlated with MPR and negatively correlated with LV filling pressure (E/e’).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Baseline correlations between sphingolipids and ceramides and key measures of cardiac structure and function</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Biomarker</th><th align="left">LV m:v</th><th align="left">GLS</th><th align="left">GCS</th><th align="left">LongPEDSR</th><th align="left">CircPEDSR</th><th align="left">MPR</th><th align="left">E/e’</th></tr></thead><tbody><tr><td align="left" colspan="8"><bold><italic>Sphingomyelin species</italic></bold></td></tr><tr><td align="left"> Hydroxypalmitoyl sphingomyelin (d18:1/16:0(OH))</td><td align="left"><bold>-0.348</bold><sup><bold>a</bold></sup></td><td align="left">0.117</td><td align="left">0.042</td><td align="left">0.226</td><td align="left"><bold>0.463</bold><sup><bold>b</bold></sup></td><td align="left">0.105</td><td align="left">-0.207</td></tr><tr><td align="left"> Sphingomyelin (d18:2/16:0, d18:1/16:1)</td><td align="left"><bold>-0.320</bold><sup><bold>a</bold></sup></td><td align="left">0.123</td><td align="left">-0.032</td><td align="left">0.279</td><td align="left"><bold>0.325</bold><sup><bold>a</bold></sup></td><td align="left">0.033</td><td align="left">0.330</td></tr><tr><td align="left"> Sphingomyelin (d18:2/24:1, d18:1/24:2)</td><td align="left"><bold>-0.384</bold><sup><bold>b</bold></sup></td><td align="left">0.211</td><td align="left">-0.185</td><td align="left"><bold>0.336</bold><sup><bold>a</bold></sup></td><td align="left"><bold>0.408</bold><sup><bold>b</bold></sup></td><td align="left">0.263</td><td align="left">-0.198</td></tr><tr><td align="left"> Sphingomyelin (d18:1/22:2, d18:2/22:1, d16:1/24:2)</td><td align="left">-0.177</td><td align="left">0.201</td><td align="left">0.032</td><td align="left"><bold>0.368</bold><sup><bold>b</bold></sup></td><td align="left"><bold>0.423</bold><sup><bold>b</bold></sup></td><td align="left">0.037</td><td align="left">0.084</td></tr><tr><td align="left"> Sphingomyelin (d18:1/20:2, d18:2/20:1, d16:1/22:2)</td><td align="left">-0.178</td><td align="left">0.090</td><td align="left">-0.048</td><td align="left">0.249</td><td align="left"><bold>0.361</bold><sup><bold>a</bold></sup></td><td align="left">-0.047</td><td align="left">0.063</td></tr><tr><td align="left"> Sphingomyelin (d18:2/18:1)</td><td align="left">-0.188</td><td align="left">0.057</td><td align="left">-0.088</td><td align="left">0.233</td><td align="left">0.236</td><td align="left">0.040</td><td align="left">0.001</td></tr><tr><td align="left"> Sphingomyelin (d18:2/23:1)</td><td align="left">-0.138</td><td align="left">0.207</td><td align="left">-0.032</td><td align="left"><bold>0.384</bold><sup><bold>b</bold></sup></td><td align="left"><bold>0.378</bold><sup><bold>b</bold></sup></td><td align="left">0.122</td><td align="left">0.089</td></tr><tr><td align="left"> Sphingomyelin (d18:2/24:2)</td><td align="left">-0.264</td><td align="left">0.216</td><td align="left">-0.003</td><td align="left"><bold>0.374</bold><sup><bold>b</bold></sup></td><td align="left"><bold>0.419</bold><sup><bold>b</bold></sup></td><td align="left">-0.037</td><td align="left">0.020</td></tr><tr><td align="left" colspan="8"><bold><italic>Ceramide species</italic></bold></td></tr><tr><td align="left"> Glycosyl ceramide (d18:2/24:1, d18:1/24:2)</td><td align="left"><bold>-0.388</bold><sup><bold>b</bold></sup></td><td align="left">0.139</td><td align="left">-0.137</td><td align="left"><bold>0.344</bold><sup><bold>b</bold></sup></td><td align="left"><bold>0.340</bold><sup><bold>a</bold></sup></td><td align="left">0.212</td><td align="left">-0.165</td></tr><tr><td align="left"> Glycosyl-N-nervonoyl-sphingosine (d18:1/24:1)<sup>+</sup></td><td align="left"><bold>-0.395</bold><sup><bold>b</bold></sup></td><td align="left">0.063</td><td align="left">-0.167</td><td align="left">0.260</td><td align="left">0.124</td><td align="left">0.186</td><td align="left">-0.058</td></tr><tr><td align="left"> Lactosyl-N-nervonoyl-sphingosine (d18:1/24:1)</td><td align="left"><bold>-0.473</bold><sup><bold>b</bold></sup></td><td align="left">0.079</td><td align="left">-0.244</td><td align="left">0.129</td><td align="left">0.102</td><td align="left">0.268</td><td align="left">-0.266</td></tr><tr><td align="left"> Lactosyl-N-palmitoyl-sphingosine (d18:1/16:0)</td><td align="left"><bold>-0.458</bold><sup><bold>b</bold></sup></td><td align="left">-0.074</td><td align="left">-0.226</td><td align="left">-0.002</td><td align="left">0.064</td><td align="left"><bold>0.312</bold><sup><bold>a</bold></sup></td><td align="left"><bold>-0.363</bold><sup><bold>a</bold></sup></td></tr></tbody></table><table-wrap-foot><p>Data reported are Spearmans Rank correlation co-efficient or <sup>+</sup>Pearsons correlation coefficient</p><p><italic>Abbreviations</italic>: <italic>LV</italic> left ventricular, <italic>m:v</italic> mass to volume ratio, <italic>GLS</italic> global longitudinal strain, <italic>GCS</italic> global circumferential strain, <italic>LongPDESR</italic> longitudinal peak early diastolic function, <italic>Circ</italic> circumferental, <italic>MPR</italic> myocardial perfusion reserve, <italic>E/e’</italic> diastolic function</p><p><sup>a</sup>Correlation is significant at the 0.05 level</p><p><sup>b</sup>Correlation is significant at the 0.01 level</p></table-wrap-foot></table-wrap></p>
                <p id="Par27">The results of the univariate analysis are displayed in Table <xref rid="Tab4" ref-type="table">4</xref>. There was no association between change in LV mass:volume ratio, change in circumferential PEDSR, change in MPR nor change in E/e’ and change in sphingolipid/ceramide species that were shown to be significantly correlated at baseline. However, there was an inverse relationship between change in two sphingolipids and change in longitudinal PEDSR (Table <xref rid="Tab4" ref-type="table">4</xref>) which did not remain significant after adjustment for baseline values (β = -0.25 (95%CI: -0.50, -0.00), <italic>p</italic> = 0.05 and β = -0.16 (95%CI: -0.32, 0.01), <italic>p</italic> = 0.06 for Sphingomyelin (d18:2/16:0, d18:1/16:1) and Sphingomyelin (d18:2/24:2), respectively).
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Relationship between change in LV mass/LVmass:volume ratio and strain rates and change in sphingolipids and ceramides at 12-weeks post MRP</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><bold>Β coefficient (95%CI)</bold></th><th align="left"><bold><italic>p</italic></bold><bold> value</bold></th><th align="left"><bold>Β coefficient (95%CI)</bold></th><th align="left"><bold><italic>p</italic></bold><bold> value</bold></th><th align="left"><bold>Β coefficient (95%CI)</bold></th><th align="left"><bold><italic>p</italic></bold><bold> value</bold></th><th align="left"><bold>Β coefficient (95%CI)</bold></th><th align="left"><bold><italic>p</italic></bold><bold> value</bold></th><th align="left"><bold>Β coefficient (95%CI)</bold></th><th align="left"><bold><italic>p</italic></bold><bold> value</bold></th></tr></thead><tbody><tr><td align="left"><bold><italic>Δ</italic></bold><bold> Candidate Biomarker</bold></td><td align="left" colspan="2"><bold><italic>Δ LV mass</italic></bold></td><td align="left" colspan="2"><bold><italic>Δ LongPEDSR</italic></bold></td><td align="left" colspan="2"><bold><italic>Δ CircPEDSR</italic></bold></td><td align="left" colspan="2"><bold><italic>Δ MPR</italic></bold></td><td align="left" colspan="2"><bold><italic>Δ E/e’</italic></bold></td></tr><tr><td align="left" colspan="11"><bold><italic>Sphingomyelin species</italic></bold></td></tr><tr><td align="left"> Hydroxypalmitoyl sphingomyelin (d18:1/16:0(OH))</td><td align="left">9.65 (-17.17, 36.46)</td><td align="left">0.481</td><td align="left"/><td align="left"/><td align="left">-0.04 (-0.39, 0.31)</td><td align="left">0.820</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Sphingomyelin (d18:2/16:0, d18:1/16:1)</td><td align="left">4.43(-30.90, 39.74)</td><td align="left">0.806</td><td align="left">-0.31 (-0.56, -0.07)</td><td align="left"><bold>0.013*</bold></td><td align="left">-0.26 (-0.70, 0.19)</td><td align="left">0.260</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Sphingomyelin (d18:2/24:1, d18:1/24:2)</td><td align="left">7.51(-28.00, 43.02)</td><td align="left">0.678</td><td align="left">-0.23 (-0.49, 0.04)</td><td align="left">0.098</td><td align="left">-0.10 (-0.56, 0.36)</td><td align="left">0.672</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Sphingomyelin (d18:1/22:2, d18:2/22:1, d16:1/24:2)</td><td align="left">-7.25 (-29.94, 15.45)</td><td align="left">0.531</td><td align="left">-0.16 (-0.33, 0.00)</td><td align="left">0.056</td><td align="left">-0.20 (-0.48, 0.08)</td><td align="left">0.164</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Sphingomyelin (d18:1/20:2, d18:2/20:1, d16:1/22:2)</td><td align="left">-7.01 (-24.08, 10.07)</td><td align="left">0.421</td><td align="left"/><td align="left"/><td align="left">-0.11 (-0.33, 0.11)</td><td align="left">0.326</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Sphingomyelin (d18:2/18:1)</td><td align="left">-8.04(-30.59, 14.52)</td><td align="left">0.485</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Sphingomyelin (d18:2/23:1)</td><td align="left">-2.55(-27.39, 22.29)</td><td align="left">0.841</td><td align="left"/><td align="left"/><td align="left">0.70 (-0.25, 0.39)</td><td align="left">0.669</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Sphingomyelin (d18:2/24:2)</td><td align="left">-4.33(-26.50, 17.85)</td><td align="left">0.702</td><td align="left">-0.17 (-0.33, -0.01)</td><td align="left"><bold>0.037*</bold></td><td align="left">-0.16 (-0.44, 0.12)</td><td align="left">0.275</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="11"><bold><italic>Ceramide species</italic></bold></td></tr><tr><td align="left"> Glycosyl Ceramide (d18:2/24:1, d18:1/24:2)</td><td align="left">-3.71 (-21.62, 14.19)</td><td align="left">0.685</td><td align="left">-0.12 (-0.25, 0.01)</td><td align="left">0.081</td><td align="left">0.15 (-0.07, 0.37)</td><td align="left">0.189</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Glycosyl-N-nervonoyl-sphingosine (d18:1/24:1)</td><td align="left">2.30 (-19.79, 24.39)</td><td align="left">0.838</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Lactosyl-N-nervonoyl-sphingosine (d18:1/24:1)</td><td align="left">4.05(-19.96, 28.06)</td><td align="left">0.741</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Lactosyl-N-palmitoyl-sphingosine (d18:1/16:0)</td><td align="left">2.42(-27.84, 32.68)</td><td align="left">0.876</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">0.06 (-0.01, 0.13)</td><td align="left">0.068</td><td align="left">0.01 (-0.01, 0.03)</td><td align="left">0.202</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic>: <italic>CI</italic> Confidence Interval, <italic>Δ change, LV</italic> Left Ventricular, <italic>M:V</italic> mass to volume ratio, <italic>Long</italic> longitudinal, <italic>PEDSR</italic> Peak Early Diastolic Strain Rate, <italic>Circ</italic> Circumferential, <italic>MPR</italic> Myocardial Perfusion Reserve, <italic>E/e’</italic> diastolic function</p><p><sup>*</sup><italic>P</italic> ≥ 0.05 following adjustment for baseline values</p></table-wrap-foot></table-wrap></p>
              </sec>
            </sec>
            <sec id="Sec13">
              <title>Discussion</title>
              <p id="Par28">In this pilot discovery study 12 lipid species were identified, eight sphingolipids and four ceramides, in the asymptomatic T2D cohort, that were down regulated at baseline and following a 12-week MRP increased towards healthy control levels. Of these 12 candidate lipids; there were negative correlations between seven and LV mass/volume ratio and one with LV E/e’ and positive correlations between five and longitudinal PEDSR, eight and circumferential PESDR and one with MPR. This data indicates that high levels of these long-chained unsaturated sphingolipid and ceramide species are associated with less concentric remodelling (lower LV mass:volume ratio), better myocardial microvascular function (higher MPR) and better diastolic function (higher PEDSR and lower E/e’). However, following the MRP the change in only two circulating plasma sphingolipids were associated with a change in diastolic strain rate, specifically a reduction in diastolic strain rate (lower longitudinal PESDR), but this did not remain significant when adjusting for baseline values. Collectively these data cast doubt on the putative causative role of these lipid molecules in the development of HFpEF.</p>
              <p id="Par29">There are many ceramide and sphingomyelin species, determined by the specifics of the fatty acids they carry and can be grouped into long and short chain species, which lends itself to the myriad of functions these lipids have. The sphingolipids, shown to be significantly reduced in our participants with T2D, are involved in numerous cellular processes that could be involved in the development of HFpEF in T2D including; cell cycle arrest, apoptosis, senescence and other stress responses [<xref ref-type="bibr" rid="CR15">15</xref>]. This is in addition to a number of important biophysiological processes including; oxidative stress and inflammation [<xref ref-type="bibr" rid="CR16">16</xref>], endothelial dysfunction [<xref ref-type="bibr" rid="CR17">17</xref>], lipotoxicity [<xref ref-type="bibr" rid="CR18">18</xref>], and insulin resistance [<xref ref-type="bibr" rid="CR19">19</xref>] which may also play a role in the pathogenesis of HFpEF in T2D. Indeed, there has been an emergence of evidence linking these bioactive lipids to the development of chronic conditions such as T2D or HF [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. The majority of the evidence in humans is derived from large prospective studies with the associated risk thought to be determined by the composition of the fatty acid moiety. That is the length (number of carbons) and number of double bonds present in the fatty acid chains of the sphingolipid/ceramide species, specifically, longer chained saturated fatty acids are reportedly associated with lower risk [<xref ref-type="bibr" rid="CR22">22</xref>]. Notably, each species identified in our study contained at least one long-chain fatty acid that was polyunsaturated.</p>
              <sec id="Sec14">
                <title>Case–control</title>
                <p id="Par30">Our data show lower levels of circulating long-chain polyunsaturated ceramide and sphingolipid species in adults with asymptomatic T2D (Stage A/B HF) compared to healthy controls. The Cardiovascular Health Study (CHS) [<xref ref-type="bibr" rid="CR21">21</xref>] reported that longer-chain sphingolipids (Cer-20 and -22, SM-20 and -22) are associated with a lower risk of HF even after adjustment for traditional risk factors and shorter chain species (Cer-16) irrespective of HF type. Previously, 24 HFpEF patients were compared with 38 aged matched controls without a history of heart failure from the Alberta HEART study [<xref ref-type="bibr" rid="CR11">11</xref>]. In line with our findings they found 14 sphingomyelin species, of which 12 were longer chain and/or polyunsaturated (C16.1 to C26.0/1), to be down regulated in those with established HFpEF compared to controls. Cheng et al., have also reported significantly lower plasma levels of sphingomyelin (C20:2) in 73 Stage C HF <italic>vs</italic>. 51 controls [<xref ref-type="bibr" rid="CR23">23</xref>]. This supports the baseline correlations we observed between higher circulating levels of the long-chain sphingolipid/ceramide species and less concentric remodelling (lower LV mass:volume ratio), better myocardial microvascular function (higher MPR) and better diastolic function (higher PEDSR and lower E/e’).</p>
                <p id="Par31">In a larger cohort of patients with HFpEF (<italic>n</italic> = 282) compared to non-HF controls (<italic>n</italic> = 191) from the CATHGEN biorepository [<xref ref-type="bibr" rid="CR24">24</xref>], evidence of impaired or dysregulated fatty acid oxidation in HFpEF was reported. In their targeted mass spectrometry study, they quantified 63 metabolites (45 acylcarnitines and 15 amino acids) and reported long-chain acylcarnitine’s to be significantly higher in HFrEF than HFpEF, with levels increasing linearly with declining left ventricular ejection fraction [<xref ref-type="bibr" rid="CR25">25</xref>]. The key functions of carnitine and its derivatives are to; 1) shuttle long-chain fatty acids across the mitochondrial membrane for energy generation via β-oxidation and, 2) to act as a scavenger by binding and eliminating acyl residues generated from amino-acid metabolism [<xref ref-type="bibr" rid="CR26">26</xref>]. These results are contrary to our own for the three identified carnitine species. The conflicting results could be attributed to the difference in clinical characteristics between the cohorts studied with participants from the CATHGEN biorepository being older, greater white European representation and with overt HFpEF. Our data are suggestive of dysregulated fatty acid oxidation in asymptomatic T2D who fit the classification for Stage A/B HF compared to HC.</p>
              </sec>
              <sec id="Sec15">
                <title>Cardiac remodelling and candidate biomarkers</title>
                <p id="Par32">We found moderate inverse correlations between four ceramide and three sphingomyelin species and CMR derived LV mass/volume ratio which may indicate involvement of these lipid species in cardiovascular remodelling in T2D. LV mass/volume ratio is a key measure of cardiac concentric remodelling, an important structural abnormality in the early stages of HF [<xref ref-type="bibr" rid="CR2">2</xref>], and an adverse prognostic factor in HFpEF [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. There was evidence of concentric remodelling within our cohort of asymptomatic T2D (higher mass/volume ratio) [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
                <p id="Par33">Data from both animal and human models link sphingolipid accumulation in cardiomyocytes with cardiac hypertrophy [<xref ref-type="bibr" rid="CR29">29</xref>]. However, plasma sphingolipids are reflective of systemic sphingolipid levels and not localised levels. Thus, from the data presented here it cannot be deduced what level or indeed the composition of sphingolipids that lie within the myocardium of this cohort. The high level of circulating long-chain polyunsaturated sphingolipids may be indicative of localised shorter chain saturated sphingolipids within the myocardium. This observed inverse relationship requires confirmation in larger cohorts in conjunction with a more comprehensive multivariable analysis.</p>
              </sec>
              <sec id="Sec16">
                <title>Pre-, post-intervention</title>
                <p id="Par34">To our knowledge, this is the first study to demonstrate an increase in circulating sphingolipid and ceramide species following a low-energy diet, as part of a randomised controlled trial, in asymptomatic T2D fitting the classification of Stage A/B HF. Furthermore, the increase in levels appear to have moved towards HC levels as demonstrated by the reduced separation observed in the 3D-visulisation between HC and MRP post-intervention vs. baseline (PCA). Strikingly, the observed increase was significant across all the identified sphingolipid and ceramide species. However, we found no significant association between changes in circulating levels of these species and measures of cardiac structure and function therefore casting doubt on the putative causative role of these lipid molecules in the development of HFpEF. Perhaps it is the flux of the sphingolipid/ceramide species i.e.; the ratio of short:long chain species, that is important in the pathogenesis of HFpEF, which cannot be answered by these data, but warrants further exploration in larger longitudinal studies with targeted lipidomic analysis.</p>
              </sec>
              <sec id="Sec17">
                <title>Strengths and limitations</title>
                <p id="Par35">The major strength and novelty of this study is that we utilised samples from participants in the DIASTOLIC randomised controlled trial, with well-balanced group allocation in addition to matched healthy controls at baseline. The metabolomic data analyses was conducted blinded to group allocation. To our knowledge this is the first metabolomic analysis of a lifestyle intervention in people with asymptomatic T2D with Stage A/B HF classification that includes detailed cardiovascular structural and functional phenotyping with the gold standard technique of CMR. However, we acknowledge the main limitation relates to this study being a post-hoc analysis with limited sample size and not including all groups of the RCT due to limited funding. Metabolomic studies are a “snap-shot” in time and cannot deduce the cause for the observed levels i.e.; a metabolite could be lower because of decreased production, higher degradation and /or uptake, or both. Furthermore, circulating levels may not reflect myocardial concentrations, which are incredibly difficult to obtain from asymptomatic individuals. The metabolites identified in this pilot study require verification in a larger, prospective, validation study.</p>
              </sec>
            </sec>
            <sec id="Sec18">
              <title>Conclusion</title>
              <p id="Par36">Working aged adults with asymptomatic T2D and Stage A/B HF classification have impaired or dysregulated fatty-acid metabolism represented by reduced levels of long-chain-polyunsaturated sphingomyelin/ceramide species. However, no association between the changes in circulating levels of these species and reverse cardiac remodelling were observed. Whilst this may cast doubt on the putative causative role of these lipid species in the development of HFpEF in T2D, the reverse remodelling observed in this cohort was mild and our sample size was small, therefore we may not be sufficiently powered to detect such a relationship. The findings from this pilot work require confirmation in a larger, prospective external validation cohort with a targeted lipidomic approach.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <sec id="Sec19">
                <title>Supplementary Information</title>
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="12872_2023_3623_MOESM1_ESM.docx">
                      <caption>
                        <p><bold>Additional file 1:</bold><bold>Table S1.</bold> T2D baseline characteristics and change at 12 weeks post intervention.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher’s Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <notes notes-type="author-contribution">
              <title>Authors’ contributions</title>
              <p>All authors have contributed significantly to this manuscript in-line with the current guidelines of the International Committee of Medical Journal Editors. EMB drafted the manuscript. G.S.G and L.A recruited study participants and supervised and analysed the raw data. E.R and S.A delivered and managed the dietary intervention. T.H.C, E.M.B and A.J.M conducted the statistical analysis. G.S.G, G.P.M, E.M.B, T.Y, M.J.D, L.A, D.J.L.J, L.N, C.M and M.P.M.GB contributed to the design of the study. All authors critically revised the manuscript, read and agreed to the published version of the manuscript.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>G.S.C. was funded by the British Heart Foundation through a Clinical Research Training Fellowship (FS/16/47/32190). G.M.P was funded by the NIHR Research Trainees Coordinating Centre (CDF 2014–07-045) and with additional support from the NIHR Leicester Biomedical Research Centre.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Availability of data and materials</title>
              <p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p>
            </notes>
            <notes>
              <title>Declarations</title>
              <notes id="FPar1">
                <title>Ethics approval and consent to participate</title>
                <p id="Par37">The study is registered with <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> (NCT02590822) and has National Research Ethics Service (NRES) approval from the NRES Committee West Midlands – Coventry and Warwickshire (15/WM/0222). All participants provided informed consent prior to any data collection.</p>
              </notes>
              <notes id="FPar2">
                <title>Consent for publication</title>
                <p id="Par38">Not applicable.</p>
              </notes>
              <notes id="FPar3" notes-type="COI-statement">
                <title>Competing interests</title>
                <p id="Par39">The authors declare no competing interests.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ceriello</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Catrinoiu</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Chandramouli</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Cosentino</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Dombrowsky</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Itzhak</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management</article-title>
                  <source>Cardiovasc Diabetol</source>
                  <year>2021</year>
                  <volume>20</volume>
                  <fpage>218</fpage>
                  <pub-id pub-id-type="doi">10.1186/s12933-021-01408-1</pub-id>
                  <?supplied-pmid 34740359?>
                  <pub-id pub-id-type="pmid">34740359</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <mixed-citation publication-type="other">Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the heart failure society of america, heart failure association of the european society of cardiology, japanese heart failure society and writing committee of the universal definition of heart failure. J Card Fail. 2021;23(3):352–80.</mixed-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McHugh</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>DeVore</surname>
                      <given-names>AD</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Matsouaka</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Fonarow</surname>
                      <given-names>GC</given-names>
                    </name>
                    <name>
                      <surname>Heidenreich</surname>
                      <given-names>PA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Heart failure with preserved ejection fraction and diabetes: JACC State-of-the-art review</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2019</year>
                  <volume>73</volume>
                  <fpage>602</fpage>
                  <lpage>611</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jacc.2018.11.033</pub-id>
                  <?supplied-pmid 30732715?>
                  <pub-id pub-id-type="pmid">30732715</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pfeffer</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Shah</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Borlaug</surname>
                      <given-names>BA</given-names>
                    </name>
                  </person-group>
                  <article-title>Heart failure with preserved ejection fraction in perspective</article-title>
                  <source>Circ Res</source>
                  <year>2019</year>
                  <volume>124</volume>
                  <fpage>1598</fpage>
                  <lpage>1617</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.313572</pub-id>
                  <?supplied-pmid 31120821?>
                  <pub-id pub-id-type="pmid">31120821</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhang</surname>
                      <given-names>H-W</given-names>
                    </name>
                    <name>
                      <surname>Lv</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>L-J</given-names>
                    </name>
                    <name>
                      <surname>Guo</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Shen</surname>
                      <given-names>Y-W</given-names>
                    </name>
                    <name>
                      <surname>Nagle</surname>
                      <given-names>DG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Application of omics- and multi-omics-based techniques for natural product target discovery</article-title>
                  <source>Biomed Pharmacother</source>
                  <year>2021</year>
                  <volume>141</volume>
                  <fpage>111833</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopha.2021.111833</pub-id>
                  <?supplied-pmid 34175822?>
                  <pub-id pub-id-type="pmid">34175822</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bayeva</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sawicki</surname>
                      <given-names>KT</given-names>
                    </name>
                    <name>
                      <surname>Ardehali</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Taking diabetes to heart—deregulation of myocardial lipid metabolism in diabetic cardiomyopathy</article-title>
                  <source>J Am Heart Assoc</source>
                  <year>2013</year>
                  <volume>2</volume>
                  <fpage>e000433</fpage>
                  <pub-id pub-id-type="doi">10.1161/JAHA.113.000433</pub-id>
                  <?supplied-pmid 24275630?>
                  <pub-id pub-id-type="pmid">24275630</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ljubkovic</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gressette</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bulat</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Cavar</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bakovic</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Fabijanic</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Disturbed fatty acid oxidation, endoplasmic reticulum stress, and apoptosis in left ventricle of patients with Type 2 Diabetes</article-title>
                  <source>Diabetes</source>
                  <year>2019</year>
                  <volume>68</volume>
                  <fpage>1924</fpage>
                  <lpage>1933</lpage>
                  <pub-id pub-id-type="doi">10.2337/db19-0423</pub-id>
                  <?supplied-pmid 31391173?>
                  <pub-id pub-id-type="pmid">31391173</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Doenst</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Nguyen</surname>
                      <given-names>TD</given-names>
                    </name>
                    <name>
                      <surname>Abel</surname>
                      <given-names>ED</given-names>
                    </name>
                  </person-group>
                  <article-title>Cardiac metabolism in heart failure: implications beyond ATP production</article-title>
                  <source>Circ Res</source>
                  <year>2013</year>
                  <volume>113</volume>
                  <fpage>709</fpage>
                  <lpage>724</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.113.300376</pub-id>
                  <?supplied-pmid 23989714?>
                  <pub-id pub-id-type="pmid">23989714</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Drosatos</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Schulze</surname>
                      <given-names>PC</given-names>
                    </name>
                  </person-group>
                  <article-title>Cardiac lipotoxicity: molecular pathways and therapeutic implications</article-title>
                  <source>Curr Heart Fail Rep</source>
                  <year>2013</year>
                  <volume>10</volume>
                  <fpage>109</fpage>
                  <lpage>121</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11897-013-0133-0</pub-id>
                  <?supplied-pmid 23508767?>
                  <pub-id pub-id-type="pmid">23508767</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Park</surname>
                      <given-names>TS</given-names>
                    </name>
                    <name>
                      <surname>Hu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Noh</surname>
                      <given-names>HL</given-names>
                    </name>
                    <name>
                      <surname>Drosatos</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Okajima</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Buchanan</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ceramide is a cardiotoxin in lipotoxic cardiomyopathy</article-title>
                  <source>J Lipid Res</source>
                  <year>2008</year>
                  <volume>49</volume>
                  <fpage>2101</fpage>
                  <lpage>2112</lpage>
                  <pub-id pub-id-type="doi">10.1194/jlr.M800147-JLR200</pub-id>
                  <?supplied-pmid 18515784?>
                  <pub-id pub-id-type="pmid">18515784</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <mixed-citation publication-type="other">Zordoky BN, Sung MM, Ezekowitz J. Metabolomic fingerprint of heart failure with preserved ejection fraction. PLOS ONE. 2015;10(5):e0124844.</mixed-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gulsin</surname>
                      <given-names>GS</given-names>
                    </name>
                    <name>
                      <surname>Swarbrick</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Athithan</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Brady</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Henson</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Baldry</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effects of low-energy diet or exercise on cardiovascular function in working-age adults with Type 2 Diabetes: a prospective, randomized, open-label</article-title>
                  <source>Blinded End Point Trial Diabetes Care</source>
                  <year>2020</year>
                  <volume>43</volume>
                  <fpage>1300</fpage>
                  <lpage>1310</lpage>
                  <pub-id pub-id-type="doi">10.2337/dc20-0129</pub-id>
                  <?supplied-pmid 32220917?>
                  <pub-id pub-id-type="pmid">32220917</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brady</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Gulsin</surname>
                      <given-names>GS</given-names>
                    </name>
                    <name>
                      <surname>Mirkes</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Parke</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Kanagala</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Ng</surname>
                      <given-names>LL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Fibro-inflammatory recovery and type 2 diabetes remission following a low calorie diet but not exercise training: a secondary analysis of the DIASTOLIC randomised controlled trial</article-title>
                  <source>Diabetic Med</source>
                  <year>2022</year>
                  <volume>39</volume>
                  <fpage>e14884</fpage>
                  <pub-id pub-id-type="doi">10.1111/dme.14884</pub-id>
                  <?supplied-pmid 35587779?>
                  <pub-id pub-id-type="pmid">35587779</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gulsin</surname>
                      <given-names>GS</given-names>
                    </name>
                    <name>
                      <surname>Brady</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Swarbrick</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Athithan</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Henson</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Baldry</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Rationale, design and study protocol of the randomised controlled trial: Diabetes Interventional Assessment of Slimming or Training tO Lessen Inconspicuous Cardiovascular Dysfunction (the DIASTOLIC study)</article-title>
                  <source>BMJ Open</source>
                  <year>2019</year>
                  <volume>9</volume>
                  <fpage>e023207</fpage>
                  <pub-id pub-id-type="doi">10.1136/bmjopen-2018-023207</pub-id>
                  <?supplied-pmid 30928925?>
                  <pub-id pub-id-type="pmid">30928925</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kitatani</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Idkowiak-Baldys</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Hannun</surname>
                      <given-names>YA</given-names>
                    </name>
                  </person-group>
                  <article-title>The sphingolipid salvage pathway in ceramide metabolism and signaling</article-title>
                  <source>Cell Signal</source>
                  <year>2008</year>
                  <volume>20</volume>
                  <fpage>1010</fpage>
                  <lpage>1018</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cellsig.2007.12.006</pub-id>
                  <?supplied-pmid 18191382?>
                  <pub-id pub-id-type="pmid">18191382</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nikolova-Karakashian</surname>
                      <given-names>MN</given-names>
                    </name>
                    <name>
                      <surname>Reid</surname>
                      <given-names>MB</given-names>
                    </name>
                  </person-group>
                  <article-title>Sphingolipid metabolism, oxidant signaling, and contractile function of skeletal muscle</article-title>
                  <source>Antioxid Redox Signal</source>
                  <year>2011</year>
                  <volume>15</volume>
                  <fpage>2501</fpage>
                  <lpage>2517</lpage>
                  <pub-id pub-id-type="doi">10.1089/ars.2011.3940</pub-id>
                  <?supplied-pmid 21453197?>
                  <pub-id pub-id-type="pmid">21453197</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jozefczuk</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Guzik</surname>
                      <given-names>TJ</given-names>
                    </name>
                    <name>
                      <surname>Siedlinski</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology</article-title>
                  <source>Pharmacol Res</source>
                  <year>2020</year>
                  <volume>156</volume>
                  <fpage>104793</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.phrs.2020.104793</pub-id>
                  <?supplied-pmid 32278039?>
                  <pub-id pub-id-type="pmid">32278039</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <mixed-citation publication-type="other">Bandet CL, Tan-Chen S, Bourron O, Le Stunff H, Hajduch E. Sphingolipid metabolism: new insight into ceramide-induced lipotoxicity in muscle cells. Int J Mol Sci. 2019;20(3):479.</mixed-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <mixed-citation publication-type="other">Sokolowska E, Blachnio-Zabielska A. The role of ceramides in insulin resistance. Front Endocrinol. 2019;10:577.</mixed-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Morze</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Wittenbecher</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Schwingshackl</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Danielewicz</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Rynkiewicz</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hu</surname>
                      <given-names>FB</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Metabolomics and Type 2 Diabetes risk: an updated systematic review and meta-analysis of prospective cohort studies</article-title>
                  <source>Diabetes Care</source>
                  <year>2022</year>
                  <volume>45</volume>
                  <fpage>1013</fpage>
                  <lpage>1024</lpage>
                  <pub-id pub-id-type="doi">10.2337/dc21-1705</pub-id>
                  <?supplied-pmid 35349649?>
                  <pub-id pub-id-type="pmid">35349649</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lemaitre</surname>
                      <given-names>RN</given-names>
                    </name>
                    <name>
                      <surname>Jensen</surname>
                      <given-names>PN</given-names>
                    </name>
                    <name>
                      <surname>Hoofnagle</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>McKnight</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Fretts</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>King</surname>
                      <given-names>IB</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Plasma ceramides and sphingomyelins in relation to heart failure risk</article-title>
                  <source>Circ Heart Fail</source>
                  <year>2019</year>
                  <volume>12</volume>
                  <fpage>e005708</fpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.118.005708</pub-id>
                  <?supplied-pmid 31296099?>
                  <pub-id pub-id-type="pmid">31296099</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>GC</given-names>
                    </name>
                    <name>
                      <surname>Chai</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Yu</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Michelotti</surname>
                      <given-names>GA</given-names>
                    </name>
                    <name>
                      <surname>Grove</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Fretts</surname>
                      <given-names>AM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Serum sphingolipids and incident diabetes in a US population with high diabetes burden: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)</article-title>
                  <source>Am J Clin Nutr</source>
                  <year>2020</year>
                  <volume>112</volume>
                  <fpage>57</fpage>
                  <lpage>65</lpage>
                  <pub-id pub-id-type="doi">10.1093/ajcn/nqaa114</pub-id>
                  <?supplied-pmid 32469399?>
                  <pub-id pub-id-type="pmid">32469399</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cheng</surname>
                      <given-names>M-L</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>C-H</given-names>
                    </name>
                    <name>
                      <surname>Shiao</surname>
                      <given-names>M-S</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>M-H</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>Y-Y</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>C-Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2015</year>
                  <volume>65</volume>
                  <fpage>1509</fpage>
                  <lpage>1520</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jacc.2015.02.018</pub-id>
                  <?supplied-pmid 25881932?>
                  <pub-id pub-id-type="pmid">25881932</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kraus</surname>
                      <given-names>WE</given-names>
                    </name>
                    <name>
                      <surname>Granger</surname>
                      <given-names>CB</given-names>
                    </name>
                    <name>
                      <surname>Sketch</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Donahue</surname>
                      <given-names>MP</given-names>
                    </name>
                    <name>
                      <surname>Ginsburg</surname>
                      <given-names>GS</given-names>
                    </name>
                    <name>
                      <surname>Hauser</surname>
                      <given-names>ER</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN Experience</article-title>
                  <source>J Cardiovasc Transl Res</source>
                  <year>2015</year>
                  <volume>8</volume>
                  <fpage>449</fpage>
                  <lpage>457</lpage>
                  <pub-id pub-id-type="doi">10.1007/s12265-015-9648-y</pub-id>
                  <?supplied-pmid 26271459?>
                  <pub-id pub-id-type="pmid">26271459</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hunter</surname>
                      <given-names>WG</given-names>
                    </name>
                    <name>
                      <surname>Kelly</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>McGarrah</surname>
                      <given-names>RW</given-names>
                      <suffix>3rd</suffix>
                    </name>
                    <name>
                      <surname>Khouri</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Craig</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Haynes</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure</article-title>
                  <source>J Am Heart Assoc</source>
                  <year>2016</year>
                  <volume>5</volume>
                  <issue>8</issue>
                  <fpage>e003190</fpage>
                  <pub-id pub-id-type="doi">10.1161/JAHA.115.003190</pub-id>
                  <?supplied-pmid 27473038?>
                  <pub-id pub-id-type="pmid">27473038</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Longo</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Frigeni</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Pasquali</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Carnitine transport and fatty acid oxidation</article-title>
                  <source>Biochim Biophys Acta</source>
                  <year>2016</year>
                  <volume>1863</volume>
                  <fpage>2422</fpage>
                  <lpage>2435</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.01.023</pub-id>
                  <?supplied-pmid 26828774?>
                  <pub-id pub-id-type="pmid">26828774</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Garg</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Assadi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>WB</given-names>
                    </name>
                    <name>
                      <surname>Metherall</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Thomas</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction</article-title>
                  <source>Sci Rep</source>
                  <year>2021</year>
                  <volume>11</volume>
                  <fpage>617</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41598-020-79729-6</pub-id>
                  <?supplied-pmid 33436786?>
                  <pub-id pub-id-type="pmid">33436786</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gulsin</surname>
                      <given-names>GS</given-names>
                    </name>
                    <name>
                      <surname>Kanagala</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>DCS</given-names>
                    </name>
                    <name>
                      <surname>Cheng</surname>
                      <given-names>ASH</given-names>
                    </name>
                    <name>
                      <surname>Athithan</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Graham-Brown</surname>
                      <given-names>MPM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes</article-title>
                  <source>Ther Adv Endocrinol Metab</source>
                  <year>2019</year>
                  <volume>10</volume>
                  <fpage>2042018819861593</fpage>
                  <pub-id pub-id-type="doi">10.1177/2042018819861593</pub-id>
                  <?supplied-pmid 31308926?>
                  <pub-id pub-id-type="pmid">31308926</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sletten</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Peterson</surname>
                      <given-names>LR</given-names>
                    </name>
                    <name>
                      <surname>Schaffer</surname>
                      <given-names>JE</given-names>
                    </name>
                  </person-group>
                  <article-title>Manifestations and mechanisms of myocardial lipotoxicity in obesity</article-title>
                  <source>J Intern Med</source>
                  <year>2018</year>
                  <volume>284</volume>
                  <fpage>478</fpage>
                  <lpage>491</lpage>
                  <pub-id pub-id-type="doi">10.1111/joim.12728</pub-id>
                  <?supplied-pmid 29331057?>
                  <pub-id pub-id-type="pmid">29331057</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
